DRG Market Assessment reports

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…

China’s SCCHN market is undergoing rapid transformation, driven by the expanding use of systemic therapies beyond traditional surgery and radiotherapy. Current treatment options include…

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

China’s bladder cancer market is entering a period of accelerated expansion, as novel branded therapies reshape systemic management. A major growth driver is the expanding role of immune…

The treatment landscape for endometrial carcinoma is undergoing rapid transformation, fueled by the increasing use of immune checkpoint inhibitors and advances in molecular classification. In the…

Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Second-generation hormone therapies have expanded beyond metastatic castrate-…

The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The…

The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…